Compare SINT & SNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SINT | SNGX |
|---|---|---|
| Founded | 1996 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.1M | 11.2M |
| IPO Year | 2007 | 2006 |
| Metric | SINT | SNGX |
|---|---|---|
| Price | $2.82 | $1.41 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $11.00 | $6.00 |
| AVG Volume (30 Days) | 23.8K | ★ 222.1K |
| Earning Date | 05-14-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 59.45 | 57.03 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,018,000.00 | $119,371.00 |
| Revenue This Year | $30.26 | N/A |
| Revenue Next Year | $413.20 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.79 | $1.00 |
| 52 Week High | $6.78 | $6.23 |
| Indicator | SINT | SNGX |
|---|---|---|
| Relative Strength Index (RSI) | 52.36 | 73.76 |
| Support Level | $2.60 | $1.19 |
| Resistance Level | $2.97 | $1.47 |
| Average True Range (ATR) | 0.16 | 0.06 |
| MACD | 0.03 | 0.03 |
| Stochastic Oscillator | 55.96 | 87.88 |
SINTX Technologies Inc is an advance ceramics company that develops, manufactures, and commercializes silicon nitride biomaterials, composites, devices, and related technologies for medical and other high-value applications. It provides biomedical solutions for medical devices specializing in silicon nitride (Si3N4) for musculoskeletal and antipathogenic applications. It also manufactures silicon nitride parts for customers in the electrical, aerospace, and other industrial sectors. The company is a globalised leader in the research, development, and manufacturing of silicon nitride, and its products have been implanted in humans. The Company operates as one operating segment.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).